De nouvelles données "late-breaking" renforcent l’impact d’IQIRVO® sur l’ALP, la fatigue et le prurit dans la CBP.

Ipsen presented new clinical data on IQIRVO (elafibranor) at the EASL congress, demonstrating significant improvements in alkaline phosphatase (ALP) reduction, fatigue, and pruritus in primary biliary cholangitis (PBC) patients. Real-world data showed 59% of patients achieved ALP normalization at 6 months, while 67% of patients with moderate-to-severe fatigue showed clinically significant improvements compared to 31% on placebo at 52 weeks.